Pharsight

Epanova patents expiration

EPANOVA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9050309 ASTRAZENECA DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Jan, 2033

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9012501 ASTRAZENECA Type A gelatin capsule containing PUFA in free acid form
Feb, 2025

(1 year, 4 months from now)

US8383678 ASTRAZENECA Type a gelatin capsule containing PUFA in free acid form
Feb, 2025

(1 year, 4 months from now)

US9132112 ASTRAZENECA Type A gelatin capsule containing PUFA in free acid form
Feb, 2025

(1 year, 4 months from now)

US7960370 ASTRAZENECA Type A gelatin capsule containing PUFA in free acid form
Dec, 2026

(3 years from now)

US10117844 ASTRAZENECA DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Jan, 2033

(9 years from now)

US9050308 ASTRAZENECA DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Jan, 2033

(9 years from now)

Epanova is owned by Astrazeneca.

Epanova contains Omega-3-Carboxylic Acids.

Epanova has a total of 7 drug patents out of which 0 drug patents have expired.

Epanova was authorised for market use on 05 May, 2014.

Epanova is available in capsule;oral dosage forms.

Epanova can be used as treatment of severe hypertriglyceridemia (500 mg/dl) in adult patients as an adjunct to diet, treatment of hypertriglyceridemia.

The generics of Epanova are possible to be released after 04 January, 2033.

Drugs and Companies using OMEGA-3-CARBOXYLIC ACIDS ingredient

Market Authorisation Date: 05 May, 2014

Treatment: Treatment of hypertriglyceridemia; Treatment of severe hypertriglyceridemia (500 mg/dl) in adult patients as an adjunct to diet

Dosage: CAPSULE;ORAL

More Information on Dosage

EPANOVA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic